Other members of the EPMN-105 Study Group are listed in the appendix.
Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy
Article first published online: 4 MAR 2003
Acta Neurologica Scandinavica
Volume 107, Issue 3, pages 165–175, March 2003
How to Cite
Privitera, M. D., Brodie, M. J., Mattson, R. H., Chadwick, D. W., Neto, W., Wang, S. and for the EPMN 105 Study Group (2003), Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurologica Scandinavica, 107: 165–175. doi: 10.1034/j.1600-0404.2003.00093.x
- Issue published online: 4 MAR 2003
- Article first published online: 4 MAR 2003
- Accepted for publication November 11, 2002
Objectives – To compare topiramate (TPM) with investigator's choice of carbamazepine (CBZ) or valproate (VPA) for initial treatment in patients with newly diagnosed epilepsy.
Material and methods – In patients with epilepsy diagnosed within previous 3 months, investigators selected CBZ (600 mg/day) or VPA (1250 mg/day) as preferred therapy based on the patient's clinical presentation. Based on investigators’ treatment choice, patients (n=613) were assigned to the CBZ or VPA treatment branch. Within each branch, patients were randomized to double-blind treatment with the traditional antiepileptic drugs (CBZ or VPA), TPM 100 mg/day, or TPM 200 mg/day. Patients continued double-blind treatment until exiting the study or until 6 months after last patient randomized.
Results – No statistically significant differences between fixed doses of TPM and CBZ or VPA were observed in efficacy measures: time to exit, time to first seizure, and the proportion of patients seizure-free during the last 6 months of treatment. TPM 100 mg/day was associated with the fewest discontinuations due to adverse events.
Conclusion – In patients with newly diagnosed epilepsy, an initial target dose of TPM 100 mg/day is at least as effective as therapeutic doses of CBZ and VPA.